Spyre Therapeutics Ownership | Who Owns Spyre Therapeutics?
Spyre Therapeutics Ownership Summary
Spyre Therapeutics is owned by 54.68% institutional investors, 6.78% insiders, and 38.54% retail investors. Fmr is the largest institutional shareholder, holding 14.93% of SYRE shares.
SYRE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Spyre Therapeutics | 54.68% | 6.78% | 38.54% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Fmr | 9.06M | 14.93% | $151.85M |
| Blackrock funding, inc. /de | 5.52M | 7.37% | $180.90M |
| Fairmount funds management | 4.02M | 6.62% | $67.34M |
| Rtw investments, lp | 3.62M | 5.97% | $60.70M |
| Vanguard group | 4.04M | 5.39% | $132.19M |
| Tang capital management | 3.20M | 5.27% | $53.63M |
| Capital investors | 3.49M | 4.66% | $114.42M |
| Vr adviser | 2.69M | 4.42% | $45.01M |
| Braidwell lp | 2.58M | 4.25% | $43.21M |
| Driehaus capital management | 2.06M | 3.39% | $34.53M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Caxton | 8.92K | 6.83% | $292.19K |
| Fairmount funds management | 4.02M | 6.06% | $67.34M |
| Vr adviser | 2.69M | 2.53% | $45.01M |
| Affinity asset advisors | 1.42M | 2.07% | $23.79M |
| Tang capital management | 3.20M | 2.06% | $53.63M |
| Commodore capital lp | 1.99M | 1.63% | $33.32M |
| Braidwell lp | 2.58M | 1.28% | $43.21M |
| B group | 100.00K | 1.23% | $1.68M |
| Patient square capital lp | 150.00K | 1.05% | $4.91M |
| Boxer capital | 696.48K | 1.01% | $20.48M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 5.52M | 0.00% | 1.54M |
| Tcg crossover management | 1.10M | 0.91% | 1.10M |
| Capital investors | 3.49M | 0.02% | 1.10M |
| Vanguard group | 4.04M | 0.00% | 984.34K |
| Affinity asset advisors | 1.42M | 2.07% | 812.62K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Jefferies financial group | - | - | -1.39M |
| Farallon capital management | - | - | -666.00K |
| Adage capital partners gp | - | - | -610.20K |
| Avoro capital advisors | - | - | -598.60K |
| Logos global management lp | - | - | -500.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tcg crossover management | 1.10M | 0.91% | 1.10M | $18.45M |
| Parkman healthcare partners | 200.75K | 0.35% | 200.75K | $3.36M |
| Silverarc capital management | 187.74K | 0.85% | 187.74K | $6.15M |
| Patient square capital lp | 150.00K | 1.05% | 150.00K | $4.91M |
| Seven grand managers | 100.00K | 0.25% | 100.00K | $3.28M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Amundi | -5.00 |
| Pacific capital wealth advisors | -8.00 |
| Parallel advisors | -14.00 |
| True wealth design | -16.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 114 | -17.39% | 40,966,319 | -36.29% | 54 | 0.74% | 79 | 19.70% | 18 | -59.09% |
| Sep 30, 2025 | 132 | 1.54% | 61,991,182 | -2.57% | 102 | 0.93% | 62 | -25.30% | 42 | 68.00% |
| Jun 30, 2025 | 129 | -1.53% | 63,612,503 | 9.51% | 104 | 37.19% | 81 | 10.96% | 26 | -23.53% |
| Mar 31, 2025 | 132 | 0.76% | 62,108,053 | 3.71% | 17 | 0.13% | 73 | -23.96% | 34 | 78.95% |
| Dec 31, 2024 | 120 | - | 50,788,525 | -1.15% | 99 | 0.78% | 86 | 19.44% | 18 | -25.00% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 03, 2026 | Burrows Scott L | Chief Financial Officer | Sell | $93.29K |
| Mar 03, 2026 | Burrows Scott L | Chief Financial Officer | Sell | $8.33K |
| Mar 02, 2026 | Turtle Cameron | Chief Executive Officer | Sell | $386.66K |
| Mar 02, 2026 | Turtle Cameron | Chief Executive Officer | Sell | $246.21K |
| Feb 02, 2026 | Turtle Cameron | Chief Executive Officer | Sell | $461.59K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 9 |
| 2025 Q4 | - | 4 |
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
| 2025 Q1 | - | - |
SYRE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools